BackgroundCheck.run
Search For

Guy Carter, 41Newark, NJ

Guy Carter Phones & Addresses

Newark, NJ   

Bloomfield, NJ   

1060 Broad St APT 345, Newark, NJ 07102   

Mentions for Guy Carter

Guy Carter resumes & CV records

Resumes

Guy Carter Photo 48

Consultant-Natural Products R & D

Location:
Greater New York City Area
Industry:
Pharmaceuticals
Guy Carter Photo 49

Guy Carter

Location:
United States

Publications & IP owners

Us Patents

Antibiotics Aa-896

US Patent:
6689763, Feb 10, 2004
Filed:
Apr 25, 2002
Appl. No.:
10/132005
Inventors:
Guy Thomas Carter - New City NY
Jason Arnold Lotvin - Union NJ
Leonard Alexander McDonald - Mountainside NJ
Assignee:
Wyeth Holdings Corporation - Madison NJ
International Classification:
A61K 3170
US Classification:
514 50, 514 49, 536 284, 536 2853
Abstract:
This invention relates to new antibiotics designated AA-896-A1, AA-896-A2, AA-896-A3, AA-896-A4, AA-896-A5, AA-896-A6, AA-896-B1, AA-896-B2, AA-896-B3, AA-896-B4, AA-896-B5, AA-896-B6, AA-896-B7, AA-896-C1, AA-896-C2, AA-896-C3, AA-896-C4, AA-896-C5, AA-896-D1, AA-896-D2, AA-896-D3 and AA-896-D4 derived from the microorganism Streptomyces spp. LL-AA896 which are useful an anti-bacterial agents.

Substantially Pure Glycopeptide Antibiotics Ac-98-1; Ac-98-2; Ac-98-3; Ac-98-4 And Ac-98-5

US Patent:
6713448, Mar 30, 2004
Filed:
Apr 25, 2002
Appl. No.:
10/132012
Inventors:
Guy Thomas Carter - New City NY
Haiyin He - Washington Township NJ
Assignee:
Wyeth Holdings Corporation - Madison NJ
International Classification:
A61K 3816
US Classification:
514 8, 530317, 435118
Abstract:
The invention provides new substantially pure antibiotics designated AC-98-1, AC-98-2, AC-98-3, AC-98-4 and AC-98-5 derived from the microorganism.

Antibiotics Aw998A, Aw998B, Aw998C And Aw998D

US Patent:
7018996, Mar 28, 2006
Filed:
Jul 11, 2003
Appl. No.:
10/618520
Inventors:
Fangming Kong - River Vale NJ, US
Guy Thomas Carter - New City NY, US
Scott William Luckman - Ringwood NJ, US
Assignee:
Wyeth Holdings Corporation - Madison NJ
International Classification:
A61K 38/12
C07K 7/64
C07D 401/00
US Classification:
514183, 514 9, 530317, 540480, 540481
Abstract:
This invention relates to antibiotics selected from the group AW998A, AW998B, AW998C and AW998D derived from the microorganism designated LL-AW998, which are useful as antibacterial agents.

Antibiotics Aa-896

US Patent:
7078195, Jul 18, 2006
Filed:
Nov 14, 2003
Appl. No.:
10/713881
Inventors:
Guy Thomas Carter - New City NY, US
Jason Arnold Lotvin - Union NJ, US
Leonard Alexander McDonald - Mountainside NJ, US
Assignee:
Wyeth Holdings Corporation - Madison NJ
International Classification:
C12P 19/44
C12N 1/00
US Classification:
435 74, 435 85, 435886
Abstract:
This invention relates to new antibiotics designated AA-896-A1, AA-896-A2, AA-896-A3, AA-896-A4, AA-896-A5, AA-896-A6, AA-896-Bl, AA-896-B2, AA-896-B3, AA-896-B4, AA-896-B5, AA-896-B6, AA-896-B7, AA-896-C1, AA-896-C2, AA-896-C3, AA-896-C4, AA-896-C5, AA-896-D1, AA-896-D2, AA-896-D3 and AA-896-D4 derived from the microorganism spp. LL-AA896 which are useful an anti-bacterial agents.

Substantially Pure Glycopeptide Antibiotics Ac-98-1, Ac-98-2, Ac-98-3, Ac-98-4 And Ac-98-5

US Patent:
7183253, Feb 27, 2007
Filed:
Feb 4, 2004
Appl. No.:
10/771652
Inventors:
Guy Thomas Carter - New City NY, US
Haiyin He - Washington Township NJ, US
Assignee:
Wyeth Holdings Corp. - Madison NJ
International Classification:
A61K 38/16
US Classification:
514 8, 435118, 514317
Abstract:
The invention provides new substantially pure antibiotics designated AC-98-1, AC-98-2, AC-98-3, AC-98-4 and AC-98-5 derived from the microorganism.

Substantially Pure Glycopeptide Antibiotics Ac-98-1 ; Ac-98-2; Ac-98-3; Ac-98-4 And Ac-98-5

US Patent:
7696164, Apr 13, 2010
Filed:
Dec 13, 2006
Appl. No.:
11/638225
Inventors:
Guy Thomas Carter - New City NY, US
Haiyin He - Mahwah NJ, US
Assignee:
Wyeth - Madison NJ
International Classification:
C12P 17/16
A61K 38/16
US Classification:
514 8, 435118, 514277, 514317
Abstract:
The invention provides new substantially pure antibiotics designated AC-98-1, AC-98-2, AC-98-3, AC-98-4 and AC-98-5 derived from the microorganism.

Agents And Method Of Production Thereof

US Patent:
5510251, Apr 23, 1996
Filed:
Oct 4, 1994
Appl. No.:
8/318001
Inventors:
Guy T. Carter - Suffern NY
Margaret J. Torrey - Suffern NY
Michael Greenstein - Suffern NY
Assignee:
American Cyanamid Company - Madison NJ
International Classification:
C12P 1718
G12N 120
US Classification:
435119
Abstract:
This invention relates to new agents designated LL-F28249. alpha. , LL-F28249. beta. , LL-F28249. gamma. , LL-F28249. delta. , LLF28249. epsilon. , LL-F28249. zeta. , LL-F28249. eta. , LL-F28249. theta. , LL-F28249. iota. , LL-F28249. kappa. , LL-F28249. lambda. , LL-F28249. mu. , LL-F28249. nu. , and LL-F28249. omega. , to their production by fermentation, to methods for their recovery and concentration from crude solutions, to processes for their purification and to pharmaceutically and pharmacologically-acceptable salts thereof. The present invention includes within its scope the biologically pure culture which produces there agents, derived from a newly-discovered and previously uncultured microorganism, Streptomyces cyaneogriseus subsp. noncyanogenus, NRRL 15773.

Biologically Pure Culture Of The Microorganism, Streptomyces Cyaneogriseus Subspecies Noncyanogenus, Or A Mutant Thereof

US Patent:
5418168, May 23, 1995
Filed:
Aug 10, 1992
Appl. No.:
7/927581
Inventors:
Guy T. Carter - Suffern NY
Margaret J. Torrey - Suffern NY
Michael Greenstein - Suffern NY
Assignee:
American Cyanamid Company - Wayne NJ
International Classification:
C12N 120
C12P 1718
US Classification:
4352535
Abstract:
This invention relates to new agents designated LL-F28249. alpha. , LL-F28249. beta. , LL-F28249. gamma. , LL-F28249. delta. , LL-F28249. epsilon. , LL-F28249. zeta. , LL-F28249. eta. , LL-F28249. theta. , LL-F28249. iota. , LL-F28249. kappa. , LL-F28249. lambda. , LL-F28249. mu. , LL-F28249. nu. , and LL-F28249. omega. , to their production by fermentation, to methods for their recovery and concentration from crude solutions, to processes for their purification and to pharmaceutically and pharmacologically-acceptable salts thereof. The present invention includes within its scope the biologically pure culture which produces there agents, derived from a newly-discovered and previously uncultured microorganism, Streptomyces cyaneogriseus subsp. noncyanogenus, NRRL 15773.

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.